V CompBrief BY VELARION

Former President and Chief Executive Officer · Inhibikase Therapeutics, Inc. (IKT)

Milton Werner, Ph.D.

Milton Werner, Ph.D., Former President and Chief Executive Officer of Inhibikase Therapeutics, Inc., received total compensation of $803,063 for fiscal year 2025. His disclosed compensation includes a base salary of $728,979, a cash bonus of $31,543, and stock-based compensation of $40,449.

FY2025 is the first fiscal year CompBrief holds for Milton Werner, Ph.D. as a named executive officer of Inhibikase Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$803,063

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Milton Werner, Ph.D. compensation by year

Inhibikase Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Inhibikase Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$728,979
Bonus$0
Stock awards$0
Option awards$40,449
Non-equity incentive$31,543
Pension and deferred compensation$0
All other$2,092
Total$803,063

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inhibikase Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197177, and prior-year filings. Open the filing on EDGAR.

Inhibikase Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Mark IwickiChief Executive Officer and Director$30,586,007
Chris Cabell, M.D.President and Head of Research and Development$7,475,289
David McIntyreChief Financial Officer$5,519,690
Milton Werner, Ph.D. · this pageFormer President and Chief Executive Officer$803,063

The full Inhibikase Therapeutics compensation record

free company brief
Inhibikase Therapeutics, Inc. (IKT) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within Inhibikase Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Inhibikase Therapeutics's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $1,500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Inhibikase Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy